‘Bombshell’ Study of Pfizer COVID Vaccine Suggests Some People Got Highly Dangerous Shots, Others Got a Placebo

From Children's Health Defense:

Danish scientists uncovered compelling evidence that a significant percentage of the batches of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine distributed in the EU likely consisted of placebos — and the non-placebo batches demonstrated higher-than-normal severe adverse events in recipients.

The scientists published their study in March, as a letter submitted to the European Journal of Clinical Investigation. BNT162b2 is the vaccine granted Emergency Use Authorization from the U.S. Food and Drug Administration and other authorities.

The study initially did not attract attention, but recent media reports brought it to light.

Journalist Kim Iversen, who on Wednesday reported on the study on “The Kim Iversen Show,” called it an “absolute bombshell of a story.”

Iversen cited as her source an article in The Daily Sceptic, also published Wednesday, by five German scientists who have publicly questioned the safety of the vaccines.

The Danish researchers looked at Pfizer-BioNTech vaccines administered in Denmark between December 2020 and January 2022 and found that batches of the Pfizer-BioNTech COVID-19 vaccine could neatly be divided into three groups.

Two of the three groups demonstrated higher-than-normal percentages of severe adverse events in recipients. However, for the third group of batches, a total of zero adverse events were reported.

The researchers also examined data indicating which batches were inspected and tested by regulators and discovered that almost none of the batches from the third group — associated with no severe adverse events — had been inspected.

According to Iversen, the findings suggest that “many of the batches of the Pfizer vaccine administered to the public — up to 30% — were placebos. And even worse, the evidence points to regulators knowing about it and willingly administering them.”

The study’s authors wrote:

“The observed variation in SAE [severe adverse event] rates and seriousness between BTN162b2 vaccine batches in this nationwide study was contrary to the expected homogenous rate and distribution of SAEs between batches.

“In conclusion, the results suggest the existence of a batch-dependent safety signal for the BNT162b2 vaccine, and more studies are warranted to explore this preliminary observation and its consequences.”